Nicole Longo Nicole is director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
No matter how you structure it, government arbitration is wrong for Medicare drug coverage
By Nicole Longo | June 27, 2019
Despite concerns from a broad group of stakeholders, some in Washington continue to push for imposing government arbitration on Medicare drug coverage to set the price of a medicine....
Read More
By the numbers: A look at the Part B International Pricing Index Model
By Nicole Longo | June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...
Read More
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
By Nicole Longo | May 16, 2019
There has been broad acknowledgement in Congress and by the Administration, as well as by patient groups and some hospitals, that the 340B program is not working as Congress intended. Yet little...
Read More
Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices
By Nicole Longo | May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...
Read More
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
By Nicole Longo | April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build...
Read More
Fact Check: How the Part B International Pricing Index model threatens patient access
By Nicole Longo | March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...
Read More
New analysis finds Average Sales Price system has led to significant cost savings for Medicare and seniors
By Nicole Longo | March 7, 2019
When Congress created the Medicare Part D program as part of the Medicare Modernization Act of 2003 (MMA), it also implemented changes to Part B to make it market based with the creation of the...
Read More
Look at the facts. Drug importation is dangerous.
By Nicole Longo | February 22, 2019
Today, 1 in 10 medicines worldwide and up to 50 percent of drugs consumed in developing nations are counterfeit. Importation proposals would open the U.S. borders to these dangerous and...
Read More
ICYMI: New study reinforces dangers of proposed IPI model
By Nicole Longo | January 15, 2019
Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in...
Read More
PhRMA comments to administration on International Pricing Index Model
By Nicole Longo | January 3, 2019
As 2018 came to a close, PhRMA submitted comments on the administration’s proposed International Pricing Index (IPI) Model for Medicare Part B medicines. The comments highlighted concerns and...
Read More
Medicare Monday (100)
340B Spotlight (41)
Cost & Consequence (0)
